儿童IgA血管炎伴严重皮肤表现患者的临床特征、治疗与结局:国际多中心研究
该回顾性国际多中心研究纳入64例伴严重皮肤表现(出血性水疱、大疱、溃疡和/或坏死)的IgA血管炎(IgAV)患儿,并与596例无此类表现的IgAV患儿比较。严重皮肤表现组年龄更大、肾炎发生率更高(40.6% vs 20.6%,p=0.001)且肾脏病结局更差(p=0.001),严重胃肠道并发症更常见(29.3% vs 14.8%,p<0.001),d-二聚体更高(4.60 mg/L vs 2.72 mg/L,p=0.003),全身糖皮质激素使用更多(84.4% vs 37.2%,p<0.001)。多因素分析显示严重皮肤改变与肾炎风险升高[OR=3.1(95%CI 1.04-9.21),p=0.042]及严重胃肠道并发症风险升高[OR=3.65(95%CI 1.08-12.37),p=0.038]相关。
要点
- 伴严重皮肤表现的IgAV患儿肾炎发生率40.6%,高于无严重皮肤表现者的20.6%(p=0.001)。
- 严重皮肤改变与肾炎风险升高相关[OR=3.1(95%CI 1.04-9.21),p=0.042]。
- 严重皮肤改变与严重胃肠道并发症风险升高相关[OR=3.65(95%CI 1.08-12.37),p=0.038]。
核心结论
- 伴严重皮肤表现的IgAV/HSP患者临床病程更严重,且较经典IgAV/HSP患者更常需要糖皮质激素治疗。
研究设计与样本
- 回顾性收集来自12个国际三级大学医学中心的数据,比较64例伴严重皮肤表现(出血性水疱、大疱、溃疡和/或坏死)的IgAV/HSP患者与596例无这些表现的患者。
- 伴严重皮肤表现组发病年龄中位数(Q1,Q3)为8.08(5.08,11.92)岁,无这些表现组为6.33(4.50,8.92)岁。
主要发现
- 伴严重皮肤表现组较其他IgAV/HSP患者年龄更大(p<0.001)。
- 伴严重皮肤表现组肾炎发生率40.6% vs 无这些表现组20.6%(p=0.001),且肾脏病结局更差(p=0.001)。
- 伴严重皮肤表现组严重胃肠道并发症(便血、大量出血和/或肠套叠)发生率29.3% vs 无这些表现组14.8%(p<0.001)。
- 伴严重皮肤表现组d-二聚体浓度4.60 mg/L vs 无这些表现组2.72 mg/L(p=0.003)。
- 伴严重皮肤表现组需要全身糖皮质激素治疗的比例84.4% vs 无这些表现组37.2%(p<0.001)。
关键数值与推荐
- 严重皮肤表现定义为存在出血性水疱、大疱、溃疡和/或坏死。
- 多因素分析显示严重皮肤改变与肾炎风险升高相关[OR=3.1(95%CI 1.04-9.21),p=0.042]。
- 多因素分析显示严重皮肤改变与严重胃肠道并发症风险升高相关[OR=3.65(95%CI 1.08-12.37),p=0.038]。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: IgA vasculitis (IgAV) (formerly Henoch-Schönlein Purpura, HSP) rarely causes severe skin lesions in children. The purpose of the research was to determine whether severe skin manifestations were associated with a more severe disease course. METHODS: Severe cutaneous manifestations were defined as presence of hemorrhagic vesicles, bullae, ulcerations and/or necroses. Data were collected retrospectively from 12 international tertiary university medical centers. RESULTS: A total of 64 patients with the most severe skin changes in IgAV/HSP and median (Q1, Q3) age of 8.08 (5.08, 11.92) years at the disease onset were compared with 596 IgAV/HSP patients without these manfiestations and median (Q1, Q3) age of 6.33 (4.50, 8.92) years. The patients with severe cutaneous manifestations were older in comparison to other patients with IgAV/HSP (p<0.001), they developed nephritis more frequently (40.6% vs. 20.6%, p = 0.001) with worse outcome of renal disease (p = 0.001). This group of patients also had higher frequencies of severe gastrointestinal complications like hematochezia, massive bleeding and/or intussusception (29.3% vs. 14.8%, p<0.001). d-dimer concentrations were significantly higher in these patients (4.60 mg/L vs. 2.72 mg/L, p = 0.003) and they had more frequent need for treatment with systemic glucocorticoids (84.4% vs. 37.2%, p<0.001) in comparison with the control group. Further multivariate analysis showed that severe cutaneous changes were associated with higher risk of developing nephritis [OR=3.1 (95%CI 1.04-9.21), p = 0.042] and severe gastrointestinal complications [OR=3.65 (95%CI 1.08-12.37), p = 0.038]. CONCLUSION: Patients with IgAV/HSP and severe skin manifestations had a more severe clinical course and more frequently required glucocorticoids compared to classic IgAV/HSP patients.
引用
- Sestan M, Kifer N, Sozeri B, et al. Clinical features, treatment and outcome of pediatric patients with severe cutaneous manifestations in IgA vasculitis: Multicenter international study. Semin Arthritis Rheum. 2023. PMID: 37126983. doi:10.1016/j.semarthrit.2023.152209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。